Consequently, it would be difficult to show the real effect of the MTHFR rs1801133 polymorphism on the AD risk in the overall study population rather than among the non-ApoE ε4 carriers only without confounder-controlling stratification. This evidence concerns the gene MTHFR and Alzheimer disease.